Evidence map›Paper›PMID 31191343›Full record

ReviewFrontiers in physiology2019

Heart Failure With Preserved Ejection Fraction: A Review of Cardiac and Noncardiac Pathophysiology.

Andreas B Gevaert, Jente R A Boen, Vincent F Segers, Emeline M Van Craenenbroeck

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 2 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Observational
  7. Article
  8. Article
  9. Review
  10. Article
  11. Low and High Pressor Doses of Ang II Lead to Two Distinct Phenotypes of Hypertensive Heart Disease in Mice.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026
    Article
  12. Cellular basis of HFpEF: contributions of abnormal lipids.Frontiers in cardiovascular medicine · 2026
    Review
  13. Review
  14. Review
  15. Prognostic impact of cardiac dysfunctions in patients with ST-segment elevation myocardial infarction.American heart journal plus : cardiology research and practice · 2025
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Andreas B GevaertResearch Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium.
Jente R A BoenResearch Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium.
Vincent F SegersDepartment of Cardiology, Antwerp University Hospital (UZA), Edegem, Belgium.
Emeline M Van CraenenbroeckResearch Group Cardiovascular Diseases, GENCOR Department, University of Antwerp, Antwerp, Belgium.
University of Antwerp · BEAntwerp University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure with preserved ejection fraction (HFpEF) is one of the largest unmet clinical needs in 21st-century cardiology. It is a complex disorder resulting from the influence of several comorbidities on the endothelium. A derangement in nitric oxide bioavailability leads to an intricate web of physiological abnormalities in the heart, blood vessels, and other organs. In this review, we examine the contribution of cardiac and noncardiac factors to the development of HFpEF. We zoom in on recent insights on the role of comorbidities and microRNAs in HFpEF. Finally, we address the potential of exercise training, which is currently the only available therapy to improve aerobic capacity and quality of life in HFpEF patients. Unraveling the underlying mechanisms responsible for this improvement could lead to new biomarkers and therapeutic targets for HFpEF.

Indexed as

comorbiditiesendotheliumexercise intoleranceheart failureiron deficiencymicroRNApathophysiology

Identifiers

PMID31191343
PMCPMC6548802
OpenAlexW2947682405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.